What one share of MIRA Pharmaceuticals holds
Pharmaceuticals, Inc. (NASDAQ: MIRA, the “Company”, “we”, “us”) is a clinical-stage pharmaceutical development company advancing a pipeline of novel oral therapeutics targeting neurologic, neuropsychiatric, metabolic, and addiction-related disorders.
MIRA Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.26 |
|---|---|
| Cash and investments | $0.09 |
| Book value | $0.19 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$0.40 | — | — | — | −$0.04 |
| 2023 | — | −$0.86 | — | — | — | $0.30 |
| 2024 | — | −$0.51 | — | — | — | $0.13 |
| 2025 | — | −$1.35 | — | — | — | $0.25 |
Common questions about MIRA Pharmaceuticals
How much does one share of MIRA Pharmaceuticals earn?
Over the last 12 months, MIRA Pharmaceuticals lost $0.26 for each share.
Does MIRA Pharmaceuticals pay a dividend?
MIRA Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is MIRA Pharmaceuticals’s book value per share?
MIRA Pharmaceuticals’s book value is $0.19 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of MIRA Pharmaceuticals have?
Each share of MIRA Pharmaceuticals has $0.09 of cash and investments, as of June 30, 2026.
Has MIRA Pharmaceuticals bought back shares?
MIRA Pharmaceuticals’s share count rose about 35% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.